Quick Answer
HALOZYME THERAPEUTICS, INC. reported Total Revenue of $1.40 billion for fiscal year 2025.
HALOZYME THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.40B +37.6% |
$1.02B +22.4% |
$829.25M +25.6% |
$660.12M +48.9% |
$443.31M +65.7% |
$267.59M +36.5% |
| Revenue (ASC 606) | $1.40B +37.6% |
$1.02B +22.4% |
$829.25M +25.6% |
$660.12M +48.9% |
$443.31M +65.7% |
$267.59M +36.5% |
| Net Income | $316.89M -28.6% |
$444.09M +57.7% |
$281.59M +39.3% |
$202.13M -49.8% |
$402.71M +212.0% |
$129.09M +278.7% |
| Diluted EPS | $2.56 -25.4% |
$3.43 +63.3% |
$2.10 +45.8% |
$1.44 -47.4% |
$2.74 +201.1% |
$0.91 +282.0% |
| Total Assets | $2.53B +22.4% |
$2.06B +19.1% |
$1.73B -5.9% |
$1.84B +66.7% |
$1.10B +90.4% |
$579.92M +2.5% |
| Cash and Equivalents | $133.82M +15.5% |
$115.85M -2.1% |
$118.37M -49.5% |
$234.19M +97.3% |
$118.72M -19.6% |
$147.70M +22.9% |
| Long-Term Debt | $2.14B +42.3% |
$1.51B +0.4% |
$1.50B +0.4% |
$1.49B +89.6% |
$787.25M | $0.00 -100.0% |
| Stockholders Equity | $48.81M -86.6% |
$363.82M +334.1% |
$83.81M -50.6% |
$169.80M -13.8% |
$196.95M +30.4% |
$151.05M +64.6% |
| R&D Expense | — | $79.05M +3.5% |
$76.36M +14.6% |
$66.61M +86.7% |
$35.67M +4.2% |
$34.24M -75.7% |
| Operating Income | $469.01M -15.0% |
$551.48M +63.4% |
$337.57M +26.2% |
$267.53M -3.0% |
$275.90M +91.3% |
$144.25M +313.4% |
| Shares Outstanding | 117.78M -4.3% |
123.14M -2.9% |
126.77M -6.2% |
135.15M -1.7% |
137.50M +1.8% |
135.03M -1.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $354.26M | +22.1% | +8.8% |
| Revenue (ASC 606) | September 30, 2025 | $354.26M | +22.1% | +8.8% |
| Net Income | September 30, 2025 | $175.22M | +27.9% | +6.1% |
| Diluted EPS | September 30, 2025 | $1.43 | +36.2% | +7.5% |
| Total Assets | September 30, 2025 | $2.22B | +4.9% | +8.1% |
| Cash and Equivalents | September 30, 2025 | $419.67M | +171.9% | +578.4% |
| Long-Term Debt | September 30, 2025 | $800.07M | -46.8% | -47.0% |
| Stockholders Equity | September 30, 2025 | $503.92M | +11.3% | +51.4% |
| R&D Expense | September 30, 2025 | $17.25M | -6.5% | -1.7% |
| Operating Income | September 30, 2025 | $217.92M | +33.5% | +7.6% |
| Shares Outstanding | September 30, 2025 | 117.52M | -7.6% | -0.1% |
- HALOZYME THERAPEUTICS, INC. reported Total Revenue of $1.40 billion for fiscal year 2025.
- HALOZYME THERAPEUTICS, INC. showed an increase of +37.6% in Total Revenue compared to the prior fiscal year.
- HALOZYME THERAPEUTICS, INC. reported Revenue (ASC 606) of $1.40 billion for fiscal year 2025.
- HALOZYME THERAPEUTICS, INC. showed an increase of +37.6% in Revenue (ASC 606) compared to the prior fiscal year.
- HALOZYME THERAPEUTICS, INC. reported Net Income of $316.89 million for fiscal year 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -28.6% in Net Income compared to the prior fiscal year.
- HALOZYME THERAPEUTICS, INC. reported Diluted EPS of $2.56 per share for fiscal year 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -25.4% in Diluted EPS compared to the prior fiscal year.
- HALOZYME THERAPEUTICS, INC. reported Total Assets of $2.53 billion for fiscal year 2025.
- HALOZYME THERAPEUTICS, INC. showed an increase of +22.4% in Total Assets compared to the prior fiscal year.
- HALOZYME THERAPEUTICS, INC. reported Cash and Equivalents of $133.82 million for fiscal year 2025.
- HALOZYME THERAPEUTICS, INC. showed an increase of +15.5% in Cash and Equivalents compared to the prior fiscal year.
- HALOZYME THERAPEUTICS, INC. reported Long-Term Debt of $2.14 billion for fiscal year 2025.
- HALOZYME THERAPEUTICS, INC. showed an increase of +42.3% in Long-Term Debt compared to the prior fiscal year.
- HALOZYME THERAPEUTICS, INC. reported Stockholders Equity of $48.81 million for fiscal year 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -86.6% in Stockholders Equity compared to the prior fiscal year.
- HALOZYME THERAPEUTICS, INC. reported R&D Expense of $79.05 million for fiscal year 2024.
- HALOZYME THERAPEUTICS, INC. showed an increase of +3.5% in R&D Expense compared to the prior fiscal year.
- HALOZYME THERAPEUTICS, INC. reported Operating Income of $469.01 million for fiscal year 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -15.0% in Operating Income compared to the prior fiscal year.
- HALOZYME THERAPEUTICS, INC. reported Shares Outstanding of 117.78 million shares for fiscal year 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -4.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: